Shares in GW Pharmaceuticals (GWPH) surged 21% in Tuesday’s trading, after the cannabis biopharma reported beats all round on the back of strong Epidiolex …
Cannabis stock GW Pharma (GWPH) has announced that the US Food and Drug Administration (FDA) has approved Epidiolex oral solution for the treatment …
Cannabinoid prescription medicines stock GW Pharmaceuticals (GWPH) has reported particularly strong first quarter earnings results, with US sales of Epidiolex at $116.1M, up …
GW Pharmaceuticals (GWPH) announced on Monday that it had received approval to sell its epilepsy drug in the world’s largest market, as measured …
The good news for GW Pharmaceuticals (GWPH) was it generated a profit in its latest reporting period. The bad news is it was …
June has been one roller coaster ride for cannabis stocks. First, the FDA reported that CBD be treated like a drug causing cannabis …
GW Pharmaceuticals (GWPH) has recently bounced after a solid earnings report. It also announced its phase-3 trial concerning its Epidiolex oral medicine, received …
By Genia Turanova For centuries, humans relied on plant-derived medicines, using — based on countless experiments and astute observation — a wide range …
J.P Morgan analyst Cory Kasimov initiates coverage for medical cannabis company GW Pharmaceuticals (GWPH), calling it a “clear leader” in the field of cannabinoid …
This morning, GW Pharmaceuticals (GWPH) announced that EPIDIOLEX (cannabidiol) oral solution has been transferred to Schedule V, the lowest restriction classification, by the U.S.
